Observations noting the presence of white blood cell infiltrates within tumors date back more than a century, however the cellular and molecular mechanisms regulating 
PODOJIL and MILLER in all cancers. 2, 4, 5 Therefore, the rationale exists to develop alternative immune modulatory therapies that may be functional in the nonresponder patient population.
The present review will focus on the biological activity of V-set domain containing T-cell activation inhibitor 1 (VTCN1/B7x/B7S1/ B7 homolog 4), commonly known as B7-H4, and its role in immune cell function. The main body of work completed to date has been a mix of studies assessing the ability of an agonistic B7-H4 immunoglobulin fusion protein (B7-H4 Ig) to be used as a therapeutic in mouse models of autoimmune disease, the use of B7-H4 knockout mice in various model systems, and the expression profile of B7-H4 within human tumors. While the summation of the data published to date all point toward B7-H4 functionally decreasing inflammatory CD4 + T cell directly and B7-H4 directly increasing the number and function of regulatory CD4 + T cells, the actual ability of B7-H4 blockade to decrease tumor burden will not be fully known until both consistent B7-H4 positive mouse tumor models as well as high quality anti-B7-H4 monoclonal antibodies are fully interrogated in a systematic manner.
| T-CELL ACTIVATION AND THE ROLE OF CLASSICAL B7 PROTEINS
The requirement of naive T cells to receive two signals to become fully activated was first proposed by Lafferty and Cunningham. gands. [9] [10] [11] [12] In the field of cancer immunotherapy, the use of chimeric antigen receptor (CAR) T cells has been studied to determine if tumor antigen-specific T cells will allow for lead to tumor killing and disease clearance.
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The second set of signals required for antigen-specific T-cell activation are delivered via co-stimulatory molecules that are expressed on the cell surface of activated APCs, and cytokines that are either produced by the APC and/or by the activated CD4 + T cell itself. Classically, B7-1 (CD80) and B7-2 (CD86) expressed on the surface of the APC interact with the co-receptor CD28 that is constitutively expressed on the surface of naive CD4 + T cells. 15 The overall effect of CD28 ligation is to increase the level of proliferation and cytokine production, promote cell survival, and enhance expression of CD40 ligand (CD40L) and adhesion molecules necessary for trafficking, such as very late antigen-4 (VLA-4) (α4β1 integrin). 16 Following activation, T cells begin to express the negative regulatory protein, CTLA-4 that also interacts with CD28. The costimulatory molecule pairs, CD28:CD80/CD86 and CD40:CD40L, and cellular adhesion molecules, such as VLA-4, represent putative therapeutic targets for blockade of autoreactive CD4 + T-cell activation and trafficking to inflammatory sites. For example, the blockade and conversely the stimulation of CD80/CD86:CD28/ CTLA-4 interaction has been tested clinically. In autoimmune disease indications of rheumatoid arthritis, CTLA-4 Ig has been shown to inhibit CD4 + T-cell action. 17 On the converse side of the CD80/ CD86:CD28/CTLA-4 interaction, a monoclonal antibody specific for CTLA-4 has been shown to enhance inflammatory T-cell function and tumor clearance. 4 The efficacy of the aforementioned therapeutics provided the rationale for the development of new immune-based therapeutics that can either block or conversely stimulate the same immune regulatory pathways to treat both autoimmune and cancer, respectively.
| B7 SUPERFAMILY PROTEINS
The ability of the immune system to decrease peripheral activation of self-reactive T cells is dependent on the level and type of co-stimulatory molecules expressed on the surface of APCs, and/or the type of co-stimulatory molecule receptors expressed by CD4 + T cells. 18 Alternatively, ligation of inhibitory molecules associated with CD4 + T cells during and/or following T-cell activation can effectively suppress T-cell responses. Over the past several decades, multiple B7/CD28-family members have been identified. CD80 is classically known to interact with both CD28 and CTLA-4, but more recent data show that CD80 also interacts with PD-L1/B7-H1. 19 To further confound the study of B7/CD28-family member proteins, the resultant functionality of a specific antibody treatment is also dependent upon the immune cell type targeted, as well as the specific antibody clone used. One such example is that cross-linking of CD80 on B cells induces a decrease in B-cell function and survival, 20 while crosslinking CD80 on CD4 + T cell induces an increase in inflammatory cytokine secretion and increased CD4 + T-cell survival. 21 Blockade of co-stimulatory signals, e.g. with CTLA-4 Ig to block CD28-mediated signal 2, has proven not to be the panacea for autoimmune disease therapy that was originally envisioned. However, monoclonal antibody blockade of co-inhibitory receptors, e.g. CTLA-4 and PD-1, has proven extremely useful for enhancing the immune response in cancer therapy.
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Further investigations into the ligands of the CD28 receptor have led to the identification and characterization of a set of related B7 molecules (the "B7 Superfamily"). 22, 23 There are at least eight members of the B7-family: B7-1 (CD80), B7-2 (CD86), the inducible co-stimulator ligand (ICOS-L; B7-H2), the programmed death-1 ligand (PD-L1; B7-H1), the programmed death-2 ligand (PD-L2; B7-DC), B7-H3 (B7-RP2), B7-H4, 24,25 and B7-H6. 26 Besides the typical co-stimulatory function of B7/CD28-family members, recent data show that some B7-family member proteins function by skewing 
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The ICOS/ICOS-L interaction has been shown to favor Th2 cell differentiation, and IL-4 production. 29 In contrast to this finding, the induction of local expression of ICOS Ig within a xenograft led to increased graft survival, and potentially increased the number of
+ T cells at the periphery of the graft. 30 Besides PD-L1, PD-L2 is also a ligand for PD-1, 22 and PD-L2 Ig has been shown to have a two-sixfold higher affinity for PD-1 as compared to PD-L1. 31 While a complete understanding of the biological significance of the differential PD-L2 and PD-L1 interaction with PD-1 remains to be determined, PD-L2 knockout mice exhibit reduced levels of IFN-γ, reduced IgG2a responses, and a decreased capacity to clear hepatic tumors. 32 Additionally, PD-L2 has been shown to interact with repulsion guidance molecule b (RGMb). 33 The identification of this additional re- 
| B7-HIDENTIFICATION AND EXPRESSION
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The human B7-H4 cDNA sequence has been used to identify a murine B7-H4 homolog. The level of identity between the murine and human orthologs (approximately 87%) suggests that B7-H4 is highly conserved evolutionarily.
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In contrast to other B7-family members that have tightly regulated mRNA expression patterns, B7-H4 mRNA is widely expressed.
Its expression has been found in the brain, heart, kidney, liver, lung, ovary, pancreas, placenta, prostate, skeletal muscle, skin, small intestine, spleen, stomach, testis, thymus, thymus, and uterus.
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However, despite the widespread expression of B7-H4 mRNA, the presence of B7-H4 protein on the surface of normal cells is limited. 
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Similarly, both recombinant and tumor microenvironment-derived IL-6 and IL-10 have been shown to stimulate monocyte/macrophage B7-H4 expression, 50 while GM-CSF was found to reduce B7-H4 expression. This observation is similar to the regulatory mechanism for B7-H4 expression on myeloid dendritic cells. 51 Locally produced IL-6
and IL-10 may be secreted by a combination of tumor cells, tumorassociated macrophages, and Treg cells present within the local tumor microenvironment. 52, 53 As will be discussed below, there is a functional connection between B7-H4 and the number/function of cells.
Therefore, these data provide a potential mechanistic link by which IL-6, IL-10, B7-H4, and Treg cells present in the tumor microenvironment are functionally connected. 
| B7-H4 EXPRESSION AND CANCER
| B7-H4 AND FINDINGS ASSOCIATED WITH A PUTATIVE B7-H4 RECEPTOR
| FUNCTIONAL CONNECTION BETWEEN B7-H4 AND TREGS
The association between inflammation and cancer dates back more than a century to observations noting infiltration of large numbers of white blood cells into tumors. 89 Several studies have now identified two main pathways linking inflammation and cancer. [90] [91] [92] First, the intrinsic pathway linking inflammation and cancer includes genetic alterations that lead to inflammation and carcinogenesis. Second, the extrinsic pathway linking inflammation and cancer is characterized by microbial/viral infections or autoimmune diseases that trigger chronic inflammation within tissues that are thereby associated with the eventual development of cancer. 93 In either case, both of these pathways activate pivotal transcription factors of inflammatory mediators (e.g.
NF-κΒ, STAT3, and HIF-1) resulting in the recruitment of inflammatory immune cells. 94 One such inflammatory immune cell population is the 
| USE OF ANTI-B7-H4 ANTIBODIES
Within the tumor microenvironment, the production of specific cy- 
